Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Wilms Tumor 8Rhabdoid Tumor 7Osteosarcoma 7Neuroblastoma 7Lymphoma, Non-Hodgkin 7Hepatoblastoma 7Sarcoma 6Rhabdomyosarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Medulloblastoma 6Histiocytosis, Langerhans-Cell 6Glioma 6Ependymoma 6Central Nervous System Neoplasms 5Sarcoma, Ewing 4Multiple Myeloma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Lung Neoplasms 3Colorectal Neoplasms 3Rectal Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Nasopharyngeal Carcinoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Immunoglobulin Light-chain Amyloidosis 2Endometrial Neoplasms 2Desmoid Tumors 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Fulvestrant 125Trastuzumab 114Paclitaxel 113Letrozole 108pembrolizumab 79pertuzumab 75palbociclib 75Capecitabine 72Anastrozole 72Cyclophosphamide 70Carboplatin 67abemaciclib 64exemestane 63Tamoxifen 63ribociclib 60trastuzumab deruxtecan 57Surveys and Questionnaires 51Specimen Handling 50Radiotherapy 49Docetaxel 49Magnetic Resonance Spectroscopy 48Blood Specimen Collection 40olaparib 39Standard of Care 36Biopsy 33sacituzumab govitecan 31130-nm albumin-bound paclitaxel 31Doxorubicin 30Exercise 29eribulin 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Phantoms, Imaging × 1 year × Clear all
NCT02849496 2026-05-22

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
81 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡